亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

医学 托法替尼 内科学 类风湿性关节炎 中止 队列 回顾性队列研究 Janus激酶抑制剂 混淆
作者
Shinya Hayashi,Shotaro Tachibana,Toshihisa Maeda,Mai Yamashita,Iku Shirasugi,Yuzuru Yamamoto,Hirotaka Yamada,T. Okano,Keisuke Nishimura,Yo Ueda,Sadao Jinno,Jun Saegusa,Wataru Yamamoto,Koichi Murata,Takayuki Fujii,Kenichiro Hata,Ayaka Yoshikawa,Kosuke Ebina,Yuki Etani,N. Yoshida,Hideki Amuro,Motomu Hashimoto,Ryota Hara,Masaki Katayama,Tadashi Okano,Ryosuke Kuroda
出处
期刊:Rheumatology [Oxford University Press]
被引量:1
标识
DOI:10.1093/rheumatology/kead543
摘要

Abstract Objective This multicentre, retrospective study compared the efficacy and safety of tofacitinib, baricitinib, peficitinib and upadacitinib in real-world clinical settings after minimizing selection bias and adjusting the confounding patient characteristics. Method The 622 patients were selected from the ANSWER cohort database and treated with tofacitinib (TOF), baricitinib (BAR), peficitinib (PEF) or upadacitinib (UPA). The patient’s background was matched using propensity score-based inverse probability of treatment weighting (IPTW) among four treatment groups. The values of Clinical Disease Activity Index (CDAI), C-reactive protein (CRP), and modified Health Assessment Questionnaire (mHAQ) after drug initiation and the remission or low disease activity (LDA) rates of CDAI at 6 months after drug initiation were compared among the four groups. Further, the predictive factor for TOF and BAR efficacy was analysed. Results The retention and discontinuation rates until 6 months after drug initiations were not significantly different among the four JAK inhibitors treatment groups. Mean CDAI value, CDAI remission rate, and CDAI-LDA rate at 6 months after drug initiation were not significantly different among treatment groups. Baseline CDAI (TOFA: OR 1.09, P < 0.001; BARI: OR 1.07, P < 0.001), baseline CRP (TOFA: OR 1.32, P = 0.049), baseline glucocorticoid dose (BARI: OR 1.18, 95% CI 1.01–1.38, P = 0.035), a number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (biological/targeted synthetic DMARDs) (BARI: OR 1.36, P = 0.004) were predictive factors for resistance to CDAI-LDA achievement to JAK inhibitor treatment. Conclusion The efficacy and safety of TOF, BAR, PEF and UPA were not significantly different for the treatment of patients with rheumatoid arthritis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
欢呼的馒头完成签到,获得积分10
8秒前
11秒前
六月飞雪完成签到,获得积分10
12秒前
Ren发布了新的文献求助10
13秒前
18秒前
syvshc的应助被u266829采纳,获得10
19秒前
miki完成签到 ,获得积分10
22秒前
共享精神的应助被u996067采纳,获得10
24秒前
27秒前
28秒前
29秒前
渡增越发布了新的文献求助10
33秒前
阿泽发布了新的文献求助10
34秒前
开放的丹南完成签到,获得积分10
36秒前
阿泽完成签到,获得积分10
42秒前
震动的静芙完成签到,获得积分10
51秒前
简单平蓝完成签到,获得积分10
1分钟前
syvshc的应助被u996067采纳,获得10
1分钟前
似水流年完成签到 ,获得积分10
1分钟前
顺利秋天完成签到,获得积分10
1分钟前
1分钟前
生锈的铁片完成签到 ,获得积分10
1分钟前
Hello的应助被u266829采纳,获得10
1分钟前
1分钟前
冷傲的中恶完成签到,获得积分10
2分钟前
体贴怡完成签到,获得积分10
2分钟前
爱笑的笑旋完成签到,获得积分10
2分钟前
科研通AI6.2的应助被ping采纳,获得10
2分钟前
科研通AI6.2的应助被u202114采纳,获得10
2分钟前
科研通AI6.3的应助被u202114采纳,获得10
2分钟前
2分钟前
繁荣的静竹完成签到,获得积分10
2分钟前
从容美女发布了新的文献求助10
2分钟前
madeleinli的应助被科研通管家采纳,获得10
2分钟前
奔跑的应助被科研通管家采纳,获得10
2分钟前
酷波er的应助被u308479采纳,获得10
2分钟前
3分钟前
3分钟前
科研通AI6.4的应助被u912093采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185142
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834120
捐赠科研通 7782607
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558759
邀请新用户注册赠送积分活动 2481206